厄贝沙坦与福辛普利降压效果的对比研究  

Comparison of irbesartan and fosinopril in the treatment of hypertension

作　　者：刘红军[1] 高娅丽[1] 

机构地区：[1]北京交通大学医院内科,北京100044

出　　处：《临床和实验医学杂志》2012年第9期667-668,共2页Journal of Clinical and Experimental Medicine

摘　　要：目的研究厄贝沙坦与福辛普利治疗原发性高血压病的疗效和不良反应。方法选取轻、中度原发性高血压病患者56例,随机分为两组,治疗组28例服用厄贝沙坦治疗,对照组28例服用福辛普利治疗,4周后根据血压决定维持原剂量或加用苯磺酸氨氯地平;总疗程8周。结果厄贝沙坦组治疗总有效率达92.8%,福辛普利组总有效率为89.3%,两组比较差异无统计学意义(P>0.05);治疗组不良反应发生率为10.7%,对照组为17.9%,两组比较差异无统计学意义(P>0.05)。结论厄贝沙坦治疗轻、中度原发性高血压病近期疗效明显,效果持久稳定,不良反应发生率低,适合基层医院使用。Objective To investigate the efficacy and adverse effect of irbesartan and fosinopril in the treatment of essential hypertension.Methods Fifty-six patients with essential hypertension were treated with irbesartan（n=28） and fosinopril（n=28） respectively.The use of amlodipine besylate depended on the level of blood pressure 4 wks after treatment.The total course of treatment was 8 wks.Results Total treatment efficiency of irbesartan was 92.8%,it was 89.3% in fosinopril treatment group（P0.05）.The incidence of adverse effect in irbesartan group was 10.7%,it was 17.9% in fosinopril group.Conclusion Irbesartan shows good short-term clinical outcome and has a low incidence of adverse effect in the treatment of mild-moderate essential hypertension.

关 键 词：高血压 厄贝沙坦 福辛普利 

分 类 号：R544.1[医药卫生—心血管疾病]